3.14
price down icon1.26%   -0.04
 
loading
Alumis Inc stock is traded at $3.14, with a volume of 637.16K. It is down -1.26% in the last 24 hours and down -29.60% over the past month. Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$3.18
Open:
$3.17
24h Volume:
637.16K
Relative Volume:
0.64
Market Cap:
$369.79M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1171
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
-12.53%
1M Performance:
-29.60%
6M Performance:
-62.57%
1Y Performance:
+0.00%
1-Day Range:
Value
$3.10
$3.2685
1-Week Range:
Value
$3.10
$3.70
52-Week Range:
Value
$3.10
$13.50

Alumis Inc Stock (ALMS) Company Profile

Name
Name
Alumis Inc
Name
Phone
650-231-6625
Name
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Employee
184
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ALMS's Discussions on Twitter

Compare ALMS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALMS
Alumis Inc
3.14 369.79M 0 -238.77M -216.62M -26.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.45 115.69B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
529.24 53.25B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
307.99 39.22B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
577.89 35.78B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
269.63 27.68B 3.81B -644.79M -669.77M -6.24

Alumis Inc Stock (ALMS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-10-25 Resumed Guggenheim Buy
Jan-30-25 Initiated Oppenheimer Outperform
Oct-31-24 Initiated Robert W. Baird Outperform
Oct-17-24 Initiated H.C. Wainwright Buy
Jul-23-24 Initiated Cantor Fitzgerald Overweight
Jul-23-24 Initiated Guggenheim Buy
Jul-23-24 Initiated Leerink Partners Outperform
Jul-23-24 Initiated Morgan Stanley Overweight
View All

Alumis Inc Stock (ALMS) Latest News

pulisher
Jun 11, 2025

(ALMS) Trading Advice - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 11, 2025

Guggenheim raises Alumis stock to buy with $18 price target By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Guggenheim - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Alumis resumed with a Buy at Guggenheim - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Guggenheim raises Alumis stock to buy with $18 price target - Investing.com India

Jun 10, 2025
pulisher
Jun 05, 2025

Traders Purchase High Volume of Put Options on Alumis (NASDAQ:ALMS) - Defense World

Jun 05, 2025
pulisher
Jun 01, 2025

Alumis resumed with an Overweight at Morgan Stanley - TipRanks

Jun 01, 2025
pulisher
May 30, 2025

Alumis to Present at the Jefferies Global Healthcare Investor Conference - The Manila Times

May 30, 2025
pulisher
May 29, 2025

AyurMaya Capital Management's Strategic Acquisition in Alumis Inc - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Alumis CEO to Share Late-Stage Immune Disease Pipeline Updates at Jefferies Healthcare Conference - Stock Titan

May 29, 2025
pulisher
May 29, 2025

News Flash: Analysts Just Made A Substantial Upgrade To Their Alumis Inc. (NASDAQ:ALMS) Forecasts - simplywall.st

May 29, 2025
pulisher
May 29, 2025

Alumis completes enrollment of Phase 3 ONWARD program of ESK-001 - TipRanks

May 29, 2025
pulisher
May 29, 2025

Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Alumis Advances Game-Changing Oral Psoriasis Drug: 1,700 Patients Enrolled in Phase 3 Trial - Stock Titan

May 29, 2025
pulisher
May 27, 2025

Largest borrow rate increases among liquid names - TipRanks

May 27, 2025
pulisher
May 26, 2025

FY2026 Earnings Forecast for Alumis Issued By HC Wainwright - Defense World

May 26, 2025
pulisher
May 21, 2025

Alumis completes merger with ACELYRIN, extends cash runway By Investing.com - Investing.com Canada

May 21, 2025
pulisher
May 21, 2025

Alumis completes merger with ACELYRIN, extends cash runway - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Alumis Completes Merger With ACELYRIN, Strengthens Pipeline And Cash Runway - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Alumis, Acelyrin Close Merger - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Alumis Inc. Completes Merger with ACELYRIN, Inc. - TipRanks

May 21, 2025
pulisher
May 21, 2025

ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks

May 21, 2025
pulisher
May 21, 2025

Alumis Inc. Completes Merger with ACELYRIN, Inc. to Strengthen Pipeline in Immune-Mediated Disease Therapies - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Alumis completes merger with Acelyrin - TipRanks

May 21, 2025
pulisher
May 21, 2025

Alumis Completes Merger with ACELYRIN - TradingView

May 21, 2025
pulisher
May 21, 2025

Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan

May 21, 2025
pulisher
May 19, 2025

ACELYRIN Stockholders Approve Merger with Alumis - TipRanks

May 19, 2025
pulisher
May 19, 2025

Alumis Inc. Stockholders Approve Merger with ACELYRIN - TipRanks

May 19, 2025
pulisher
May 19, 2025

How To Trade (ALMS) - news.stocktradersdaily.com

May 19, 2025
pulisher
May 16, 2025

Alumis Inc. Reports Q1 2025 Financial Results and Strategic Progress - TipRanks

May 16, 2025
pulisher
May 15, 2025

Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating - marketscreener.com

May 15, 2025
pulisher
May 14, 2025

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView

May 14, 2025
pulisher
May 14, 2025

Earnings Flash (ALMS) ALUMIS INC. Reports Q1 Revenue $17.4M - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times

May 14, 2025
pulisher
May 13, 2025

How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals

May 13, 2025
pulisher
May 13, 2025

ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Alumis Stockholders Approve Merger with ACELYRIN - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Alumis wins shareholder nod for ACELYRIN merger - Investing.com

May 13, 2025
pulisher
May 13, 2025

ACELYRIN shareholders approve Alumis merger deal - Investing.com

May 13, 2025
pulisher
May 13, 2025

Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider

May 13, 2025
pulisher
May 13, 2025

ACELYRIN-Alumis Merger Gets Green Light: New Powerhouse in Immune Disease Treatment Emerges - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Barclays PLC Has $193,000 Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World

May 13, 2025
pulisher
May 09, 2025

Mariner LLC Buys Shares of 18,122 Alumis Inc. (NASDAQ:ALMS) - Defense World

May 09, 2025
pulisher
May 08, 2025

(ALMS) On The My Stocks Page - news.stocktradersdaily.com

May 08, 2025

Alumis Inc Stock (ALMS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$98.73
price up icon 1.91%
$22.82
price down icon 1.17%
$34.84
price down icon 1.22%
$19.78
price down icon 1.88%
$106.57
price up icon 1.57%
biotechnology ONC
$269.63
price down icon 2.50%
Cap:     |  Volume (24h):